Skip to main content

Table 4. Comparison of nivolumab plus ipilimumab in glioblastoma and melanoma brain metastases

From: Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

Back to article page